Application of Platelet-rich Fibrin(PRF) Membrane in Ophthalmic Diseases
Overview
- Phase
- N/A
- Intervention
- Not specified
- Conditions
- Platelet-rich Fibrin
- Sponsor
- Lei Du
- Enrollment
- 170
- Locations
- 1
- Primary Endpoint
- Whether the macular hole is closed in participants with macular hole(Unit: yes/no)
- Status
- Active, Not Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
The goal of this clinical trial is to observe the role of PRF in treating ophthalmic diseases.The efficacy and safety of PRF were validated for four ophthalmic conditions: macular hole, pterygium, corneal ulcer, and patients undergoing trabeculectomy for glaucoma. The main question aims to answer is PRF's effectiveness in ocular surface and fundus diseases. Participants will be divided into 2 groups, the experimental group will be treated with PRF and the control group will be treated with conventional surgery, with a 12-month postoperative follow-up to determine the role of PRF on wound healing in ophthalmic diseases.
Detailed Description
Patients suffering from pterygium, macular hole, corneal ulcer, and glaucoma requiring for trabeculectomy , who visited Renmin Hospital of Whuhan University, were chosen to participate in this study. The participants were randomly divided into the experimental group (PRF group) and the control group (conventional group). The PRF group received PRF membrane treatment, while the conventional group received conventional surgical treatment. Before and after surgery, participants underwent a comprehensive ophthalmological exam at 1 week, 1 month, 3 months, 6 months, and 12 months. The outcome indicators are monitored and can vary depending on the disease. Participants with pterygium were examined for graft dissolution and complications. Participants with macular hole were monitored for hole closure, visual acuity recovery, and retinal blood flow recovery. Participants with corneal ulcer were monitored for lesion healing and complications such as degree of corneal vascularization and opacity. Participants with glaucoma were monitored for postoperative intraocular pressure (IOP), degree of conjunctival leakage in the filtration zone, and degree of scarring in the filtration zone.
Investigators
Lei Du
deputy chief physician
Renmin Hospital of Wuhan University
Eligibility Criteria
Inclusion Criteria
- •Diagnosis of macular hole confirmed by fundus examination;
- •Diagnosis of pterygium by slit lamp;
- •Patients requiring trabeculectomy for glaucoma;
- •Diagnosis of corneal ulcer confirmed by slit lamp.
Exclusion Criteria
- •Combination of other active ophthalmic diseases, such as acute conjunctivitis and uveitis;
- •Previous history of ophthalmic trauma and ophthalmic surgery;
- •Recent use of anticoagulant or antiplatelet drugs;
- •Combination of serious systemic diseases such as hypertension and diabetes mellitus.
Outcomes
Primary Outcomes
Whether the macular hole is closed in participants with macular hole(Unit: yes/no)
Time Frame: Pre-operation, and at 1 week, 1 month, 3 months, and 6 months post-operation.
Using optical coherence tomography（OCT ）to see if the macular hole is healing to compare the healing rate between the PRF membrane filling group and the ILM peeling group.
Whether the corneal ulcer is healing in participants with corneal ulcer(Unit: yes/no)
Time Frame: Pre-operation, and at 1 week, 1 month, 3 months, and 6 months post-operation.
The investigators use a slit lamp to examine the anterior segment of the eye to assess the corneal wound healing rate. The PRF membrane-covered group is compared to the control group.
Whether the wound heals completely after pterygium excision in participants with pterygium(Unit: yes/no)
Time Frame: Pre-operation, and at 1 week, 1 month, 3 months, and 6 months post-operation.
Observation of the anterior segment of the eye using a slit lamp to determine whether the wound is healed after pterygium excision and to compare the healing rate between the PRF membrane-covered group and the autologous conjunctival-covered group.
IOP in participants undergoing trabeculectomy for glaucoma(Unit: mmHg)
Time Frame: Pre-operation, and at 1 week, 1 month, 3 months, and 6 months post-operation.
Measurement of IOP using an IOP meter to compare the effect of IOP reduction in glaucoma treatment in the PRF membrane group and the amniotic membrane group.
Secondary Outcomes
- Degree of tissue scarification in participants undergoing trabeculectomy for glaucoma(Unit: mild, moderate, severe)(Pre-operation, and at 1 week, 1 month, 3 months, and 6 months post-operation.)
- Occurrence of complications in participants with corneal ulcer(Unit: rate)(Pre-operation, and at 1 week, 1 month, 3 months, and 6 months post-operation.)
- Best-corrected visual acuity (BCVA) in participants with macular hole(Unit: logMAR)(Pre-operation, and at 1 week, 1 month, 3 months, and 6 months post-operation.)
- Occurrence of complications in participants with pterygium(Unit: rate)(Pre-operation, and at 1 week, 1 month, 3 months, and 6 months post-operation.)